Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance

Royalty revenue climbed 44%, but the 2026 revenue guidance midpoint rose only about $20 million. Related Stocks: HALO ,

Read original article